Kevin Bielamowicz Institution Verified

Sourced from institutional research profiles (UAMS TRI or ARA).

High Impact

Researcher

University of Arkansas for Medical Sciences

faculty

20 h-index 166 pubs 3,207 cited

Research Areas

Links

ORCID Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Kevin Bielamowicz's research focuses on investigating novel therapeutic strategies for various pediatric and adult cancers, as well as genetic disorders. His work involves clinical trials and the exploration of immunotherapies, such as CAR-T cells, targeting specific cancer antigens in conditions like medulloblastoma and gliomas. He also studies the effects of different radiotherapy techniques on endocrine function in children treated for medulloblastoma.

His research extends to genetic syndromes, including constitutional mismatch-repair deficiency and neurofibromatosis type 1, evaluating targeted therapies like mirdametinib. Bielamowicz also contributes to the implementation of pharmacogenomics testing in clinical settings, aiming to personalize treatment approaches. His publications include work on CAR-T cell design to mitigate tumor escape and investigations into the efficacy of immunotherapies in relapsed or refractory cancers.

Bielamowicz leads a research group and has a publication record of 166 papers with over 3,200 citations, reflecting a significant contribution to his fields. He has collaborated with researchers at the University of Arkansas for Medical Sciences, including Murat Gökden and Sateesh Jayappa.

Metrics

h-index: 20
Publications: 166
Citations: 3,207

Selected Publications

Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance (2025) DOI
Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma (2025) DOI
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma (2024) DOI
ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN). (2024) DOI
Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures (2024) DOI
Central nervous system embryonal tumors with EWSR1-PLAGL1 rearrangements reclassified as INI-1 deficient tumors at relapse (2024) DOI
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study (2024) DOI
Isolated eyelid neonatal Langerhans cell histiocytosis (2024) DOI
Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer (2023) DOI
Early intervention palliative care in the pediatric population and its effects on quality of life (2023) DOI
IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study (2022) DOI
ETMR-15. Central Nervous System Embryonal Tumor with EWSR1 translocation: Evolving changes in histology, sequencing, and epigenetics at relapse in 2 patients and potential treatment implications (2022) DOI
Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma—a multi-institutional study (2021) DOI
Re-Evaluating Surgery and Re-Irradiation for Locally Recurrent Pediatric Ependymoma — a Multi-Institutional Study (2021) DOI
Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma (2021) DOI